Arizona State Retirement System Has $1.36 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Arizona State Retirement System cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,878 shares of the biopharmaceutical company’s stock after selling 616 shares during the period. Arizona State Retirement System’s holdings in Halozyme Therapeutics were worth $1,363,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Harbour Investments Inc. acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $51,000. Advisory Services Network LLC boosted its stake in Halozyme Therapeutics by 50.5% during the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 303 shares during the last quarter. Belpointe Asset Management LLC increased its position in shares of Halozyme Therapeutics by 42.0% in the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 366 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $92,000. Finally, Mendota Financial Group LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $127,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 1.8 %

NASDAQ HALO opened at $38.61 on Friday. The business has a fifty day moving average price of $39.22 and a two-hundred day moving average price of $37.77. The stock has a market capitalization of $4.91 billion, a PE ratio of 18.30, a PEG ratio of 0.47 and a beta of 1.25. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Equities analysts expect that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HALO. JMP Securities reaffirmed a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. The Goldman Sachs Group reduced their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Tuesday, December 26th. Finally, HC Wainwright increased their price target on shares of Halozyme Therapeutics from $48.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.